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ABSTRACT
Objective: GenoType MTBDRplus line probe assay (LPA) is developed for performing drug susceptibility testing (DST) for Rifampicin (RIF) and 
isoniazid in sputum specimens from smear-positive pulmonary tuberculosis (TB) patients and revised national TB control Programme (RNTCP) 
has endorsed LPA for the diagnosis of multi drug resistant TB (MDR-TB). This study was conducted to assess the potential utility of LPA for MDR-TB 
patient management.
Methods: MDR-TB suspects under RNTCP PMDT criteria C referred from different districts in Delhi state were included in the study January 2013 to 
December 2014. Sputum specimens found acid-fast bacilli positive by fluorescent microscopy were processed for LPA.
Results: Out of 3062 specimens, 2055 (67.1%) MDR-TB suspects were read as positive and specimens from 1007 (32.9%) suspects were read as 
negative in sputum smear microscopy. Out of 2019 specimens valid LPA results, 1427 were found to be pan-sensitive, 280 were MDR-TB, 40 were RIF 
monoresistant, 183 were Isoniazid (INH) monoresistant, and 89 specimens were found negative for Mycobacterium tuberculosis.
Conclusion: Routine use of LPA can substantially reduce the time to diagnosis of RIF and/or INH-resistant TB and can hence potentially enable earlier 
commencement of appropriate drug therapy and thereby facilitate prevention of further transmission of drug resistant strains.
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INTRODUCTION
Rapid determination of drug resistance can allow a customized approach 
to treatment early in the course of the disease and can potentially 
reduce morbidity, mortality, and infectiousness [1]. The World Health 
Organization and partners have proposed a Global XDR-TB response 
plan [2], which calls for wide-scale implementation of rapid methods 
to screen patients at risk of MDR-TB. Rapid tests can provide results 
within days and thus enable prompt and appropriate treatment, 
decrease morbidity and mortality and interrupt transmission.
The identification of specific mutations responsible for drug resistance 
has facilitated the development of novel, rapid molecular tools for 
drug susceptibility testing (DST). The detection of RIF resistance is 
traditionally used as a predictor of MDR-TB - its positive predictive 
value is a function of the sensitivity and specificity of RIF resistance 
testing and the prevalence of MDR and non-MDR RIF resistance, which 
is highest among previously treated cases in settings with high MDR 
prevalence and low non-MDR RIF resistance. Molecular tools are based 
on nucleic acid amplification in conjunction with electrophoresis, 
sequencing, or hybridization.
Reverse hybridization-based assays, referred to as line probe assays, 
represent a useful tool for their superior cost-effectiveness. These tests 
are based on the hybridization of specific probes for wild-type and 
mutated sequences of genes involved in drug resistance, and they show 
high specificity and medium/high sensitivity.
GenoType MTBDRplus (Hain Lifescience, Germany) enables the 
simultaneous molecular genetic identification of the M. tuberculosis 
complex and its resistance to Rifampicin (RIF) and isoniazid from 
clinical specimens or cultivated samples. The benefits of using 
GenoType MTBDRplus can detect M. tuberculosis-specific DNA and 
genetic mutations associated with drug resistance from smear-positive 
sputum specimens or culture isolates, after DNA extraction and PCR 
amplification [3]. The use of LPAs has been recommended by the 
WHO [4].
Revised national TB control Programme has also endorsed the LPA 
MTBDRplus, Hain Lifesciences, Germany for the diagnosis of MDR-TB. 
This assay is being used now as screening test across the country for all 
suspects of MDR-TB.
METHODS
This study was conducted at the Laboratory of New Delhi TB Centre 
(NDTB), New Delhi from February 2014 to December 2015.
The laboratory is certified by Central TB division, Ministry of Health 
and Family Welfare, Government of India for conducting liquid, solid 
culture and DST and LPA.
Study population
All MDR-TB suspects referred to New Delhi TB center, New Delhi during 
the period from January 2013 to December 2014 from 17 Chest Clinics 
of Delhi were included in the study.
Specimen collection
Samples from a total of three thousand and sixty two (n=3062) MDR-TB 
suspects were included in the study. All these cases were enrolled at 
different chest clinics of Delhi. Two sputum samples (spot and morning) 
were collected per patient in 50 ml sterile conical centrifuge tubes and 
were transported on same day along with duly filled request form for 
Culture and DST to New Delhi TB centre. On receipt, these specimens 
were checked for any spill or leakage. Spilled or leaked specimens, as 
well as inadequate quantity specimens, were rejected, and all others 
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were accepted for processing. In all these specimens, quality was 
examined by visual appearance. Sputum samples from 2431 (79.4%) 
suspects were found Mucoid/Mucopurulent, 227 (7.42%) were blood 
stained, and 404 (13.18%) were saliva.
Sputum smear microscopy
All manipulations with potentially infectious clinical specimens were 
performed in a Class II safety cabinet in a BSL-3 Laboratory. Smears 
were prepared from all these specimens and were subjected to 
Auramine staining. They were examined under ×400 magnification 
using a LED fluorescence microscope and graded according to WHO/
IUATLD guidelines [5].
Sputum specimens were processed using N-acetyl-cysteine-sodium 
hydroxide-NaOH decontamination (NaOH final concentration, 
1.5%) [6]. Following centrifugation, the pellet in each tube was 
suspended in 2.5 ml of phosphate buffer pH 6.8. Processed sediments 
from the same patient were pooled and mixed thoroughly. One portion 
of the sediment was used for LPA and another portion was used for 
culture in LJ media.
LPA
LPA testing was performed in three separate rooms, according to 
WHO recommendations. DNA extraction was performed in the BSL3 
laboratory. Master mix preparation, PCR, and hybridization were 
performed in separate rooms.
About 500 µl of processed sediment was used to perform the 
Genotype MTBDRplus (Hain Lifescience GmbH) assay, according to the 
manufacturer’s instructions [7]. After observation of final band pattern, 
depending on the presence or absence of bands, the results were 
interpreted as sensitive or resistant.
LPA testing on samples with invalid results was repeated using the 
stored residual extracted DNA. To consider a band valid for study 
purposes, the band intensity had to be equal or greater than the AC 
band (according to the product insert).
RESULTS
Specimens from 2055 (67.1%) MDR-TB suspects were read as positive 
and specimens from 1007 (32.9%) suspects were read as negative. 
Statistically significant difference was observed between negative and 
positive specimens among different types of sputum specimens as 
depicted by p value (Table 1).
During observation under microscope, grading was done in addition 
to identification of positive results grading of smear-positive sputum 
specimens is detailed in Table 2. Although majority of the specimens 
were graded as 1+ or 2+ among different types of specimens, no 
significant difference in p value was observed while comparing grading 
of smears.
Among the positive smears (n=2055), 304 (14.8%) were read 
as scanty, 685 (33.3%) were read as 1+, 824 (40.1%) were 2+, 
and 242 (11.8%) were 3+.
Out of 2055 smear positive specimens processed through LPA, valid 
results were found in 2019, remaining were indeterminate/invalid. 
Of 2019, 69.4% were found to be pan-sensitive, 11.7% were MDR-TB, 
3.9% were RIF monoresistant, 8.9% were INH monoresistant, and 4.3% 
specimens were found negative for M. tuberculosis (Table 3).
DISCUSSION
The routine use of LPA can substantially reduce the time to diagnosis 
of RIF and/or INH-resistant TB and can hence potentially enable 
earlier commencement of appropriate drug therapy and thereby 
facilitate prevention of further transmission of drug-resistant strains. 
This confers a major advantage to this test. Therefore, this study was 
conducted using the LPA for the diagnosis of MDR-TB among the MDR-
TB suspects.
The overall proportion of interpretable results with the 
Genotype MTBDRplus assay (92%) was significantly higher when 
compared to conventional methods (78%). The assay gave interpretable 
results in a considerable number of specimens (99) in which no 
conventional DST result was available (mostly due to contamination of 
the primary LJ culture), and detected an additional 09 MDR-TB cases.
Of the total valid LPA tests, MDR pattern was observed among 
280 (11.7%) specimens, Mono RIF resistance among 40 (3.9%) and 
mono isoniazid resistance in 183 (8.9%) specimens. These observations 
are in alliance with the national level data obtained from multiple 
laboratories. The performance of the LPA in this setting was similar to 
that reported previously, with high specificity for detection of RIF and 
isoniazid, high sensitivity for detection of RIF resistance, and isoniazid 
resistance [8].
It was observed in this study that RIF resistance was highly associated 
with mutation in the 81 base pair region of the rpoB gene. This is in 
agreement with the results published earlier [9,10]. In addition, our 
observation that Isoniazid resistance was most commonly associated 
with katG mutation was similar to the one reported earlier [11].
LPA invalid results were obtained in 7 samples and indeterminate 
results were obtained in 29 samples. Of these 36 samples, 28 were 
scanty positive and 20 were culture negative. This proves that this 
test is not suitable for smear-negative clinical specimens [12,4]. It 
was previously reported that low-grade smear positivity correlated to 
invalid results in LPA [13].
In our laboratory, around 700 specimens are processed monthly and the 
workflow is adjusted in a way that the final results of the test should be 
available within the turn-around-time (TAT). Early detection of MDR or 
RIF resistant by LPA led to the early initiation of MDR treatment. Before 
the introduction of LPA in Delhi state, only 70% of diagnosed MDR-
TB cases by conventional LJ culture and DST were put on treatment, 
and the remaining cases were either died or defaulted. But after the 
introduction of LPA, more than 90% of diagnosed cases were started on 
treatment (unpublished data). However, the impact of reduced TAT on 
patient outcomes such as sputum culture conversion, cure, mortality, 
and treatment failure also remains to be assessed but it is conceivable 
that early diagnosis of MDR-TB together with early treatment initiation 
will have a significant impact at the patient in public health level.
It was reported earlier that overall the cost of performing the 
MTDBDRplus test was lower when the assay is performed directly on 
Table 1: Direct AFB fluorescent microscopy results among different types of sputum specimens
Quality of sputum Number of MDR‑TB 
suspects (n=3062)
Smears microscopy result p (Chi‑square test)
Negative (n=1007) n (%) Positive (n=2055) n (%)
Mucoid 2431 678 (67.3) 1753 (85.3) 0.001
Bloody 227 80 (7.9) 147 (7.2) 0.001
Saliva 404 249 (24.7) 155 (7.5) 0.001
MDR-TB: Multi drug resistant tuberculosis
Table 2: Grading of smear positive sputum specimens
Quality of sputum Grading of positive smear n (%) Total positive (n=2055) p (Chi‑square test)
Scanty (n=304) 1+ (n=685) 2+ (n=824) 3+ (n=242) 
Mucoid 242 (79.55) 590 (86.49) 725 (88.02) 196 (80.95) 1753 0.837
Bloody 28 (9.09) 52 (7.78) 44 (5.39) 23 (9.52) 147 0.892
Saliva 34 (11.36) 43 (6.49) 55 (6.59) 23 (9.52) 155 0.856
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smear-positive sputum specimens [14,15]. In our study, it was not 
possible to do costing analysis due to various factors like support by the 
government in the form of new equipment and supplies in addition to 
fulfillment of manpower.
The availability of valid LPA results proved the advantages of molecular 
test over the conventional method.
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Table 3: LPA results among smear positive specimens
LPA results Number (%) n=2055
Sensitive 1427 (69.4)
MDR-TB 280 (11.7)
RIF monoresistant 40 (3.9)
INH monoresistant 183 (8.9)
MTBC negative 89 (4.3)
Invalid 7 (0.3)
Indeterminate 29 (1.4)
LPA: Line probe assay, MDR-TB: Multi drug resistant tuberculosis, 
RIF: Rifampicin, INH: Isoniazid
